METTL3 and neoplasm: In glioma, METTL3 and IGF2BP3 stabilize the mRNA of cytoplasmic polyadenylation element binding protein 2 (CPEB2) through m6A modification, which activates the SRSF5/ETS1 pathway to upregulate tight junction proteins (ZO-1, occludin, tight junction protein-5), reducing blood-tumor barrier permeability and causing chemoresistance [87].